Bundelkhand Online Journal

Necrotizing Enterocolitis Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

 Breaking News
  • No posts were found

Necrotizing Enterocolitis Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

September 17
17:47 2022
Necrotizing Enterocolitis Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Necrotizing Enterocolitis pipeline constitutes 4+ key companies continuously working towards developing 4+ Necrotizing Enterocolitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Necrotizing Enterocolitis Overview

Necrotizing enterocolitis (NEC) is a devastating disease that affects mostly the intestine of premature infants. The wall of the intestine is invaded by bacteria, which cause local infection and inflammation that can ultimately destroy the wall of the bowel (intestine). Such bowel wall destruction can lead to perforation of the intestine and spillage of stool into the infant’s abdomen, which can result in an overwhelming infection and death.

 

“Necrotizing Enterocolitis Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Necrotizing Enterocolitis Market. 

 

The Necrotizing Enterocolitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Necrotizing Enterocolitis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Necrotizing Enterocolitis treatment therapies with a considerable amount of success over the years. Necrotizing Enterocolitis Key players such as – Siolta Therapeutics, Noveome Biotherapeutics, Micregen Ltd, Lediant Biosciences, Infant Bacterial Therapeutics, and others, are developing therapies for the Necrotizing Enterocolitis treatment 
  • Necrotizing Enterocolitis Emerging therapies such as – STMC-10, ST266, MRG1061, STP-206, IBP-9414, and others are expected to have a significant impact on the Necrotizing Enterocolitis market in the coming years.   
  • In May 2016, Infant Bacterial Therapeutics initiated a randomized, double-blind, parallel-group, dose escalation placebo-controlled multicenter study to investigate the safety and tolerability of IBP-9414 administered in preterm infants
  • In July 2019, Infant Bacterial Therapeutics initiated a randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of Necrotizing Enterocolitis – The Connection Study
  • In January 2022, Infant Bacterial Therapeutics AB announced that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBP9414 is currently in Phase III development for the prevention of necrotizing enterocolitis (NEC) and improvement of feeding tolerance in preterm infants. 

Necrotizing Enterocolitis Pipeline Therapeutics Assessment

  • Necrotizing Enterocolitis Assessment by Product Type
  • Necrotizing Enterocolitis By Stage and Product Type
  • Necrotizing Enterocolitis Assessment by Route of Administration
  • Necrotizing Enterocolitis By Stage and Route of Administration
  • Necrotizing Enterocolitis Assessment by Molecule Type
  • Necrotizing Enterocolitis by Stage and Molecule Type

 

DelveInsight’s Necrotizing Enterocolitis Report covers around 4+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Necrotizing Enterocolitis Drugs Under Different Phases of Clinical Development Include:

  • STMC-106: Siolta Therapeutics
  • ST266: Noveome Biotherapeutics
  • MRG1061: Micregen Ltd
  • STP-206: Lediant Biosciences
  • IBP-9414: Infant Bacterial Therapeutics

 

Further Necrotizing Enterocolitis product details are provided in the report. Download the Necrotizing Enterocolitis pipeline report to learn more about the emerging Necrotizing Enterocolitis therapies

 

Necrotizing Enterocolitis Pipeline Analysis:

The Necrotizing Enterocolitis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Necrotizing Enterocolitis treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Necrotizing Enterocolitis Treatment.
  • Necrotizing Enterocolitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Necrotizing Enterocolitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Necrotizing Enterocolitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Necrotizing Enterocolitis Pipeline Market Drivers

  • Increasing contribution towards the research and development activities and growing awareness
  • Improved regulatory framework by the Government towards the development of new antibiotics and therapies

 

Necrotizing Enterocolitis Pipeline Market Barriers

  • High cost associated with the Necrotizing Enterocolitis treatment
  • Lack of skilled healthcare professionals to carry out Necrotizing Enterocolitis diagnosis

 

Get a Free Sample PDF Report to know more about Necrotizing Enterocolitis Pipeline Assessment

 

Scope of Necrotizing Enterocolitis Pipeline Drug Insight    

  • Coverage: Global
  • Key Necrotizing Enterocolitis Companies: Siolta Therapeutics, Noveome Biotherapeutics, Micregen Ltd, Lediant Biosciences, Infant Bacterial Therapeutics, and others
  • Key Necrotizing Enterocolitis Therapies: STMC-10, ST266, MRG1061, STP-206, IBP-9414, and others
  • Necrotizing Enterocolitis Therapeutic Assessment: Necrotizing Enterocolitis current marketed and Necrotizing Enterocolitis emerging therapies
  • Necrotizing Enterocolitis Market Dynamics:  Necrotizing Enterocolitis market drivers and Necrotizing Enterocolitis market barriers 

Request for Sample PDF Report for Necrotizing Enterocolitis Pipeline Assessment and clinical trials

 

Table of Contents

1

Necrotizing Enterocolitis Report Introduction

2

Necrotizing Enterocolitis Executive Summary

3

Necrotizing Enterocolitis Overview

4

Necrotizing Enterocolitis- Analytical Perspective In-depth Commercial Assessment

5

Necrotizing Enterocolitis Pipeline Therapeutics

6

Necrotizing Enterocolitis Late Stage Products (Phase II/III)

7

Necrotizing Enterocolitis Mid Stage Products (Phase II)

8

Necrotizing Enterocolitis Early Stage Products (Phase I)

9

Necrotizing Enterocolitis Preclinical Stage Products

10

Necrotizing Enterocolitis Therapeutics Assessment

11

Necrotizing Enterocolitis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Necrotizing Enterocolitis Key Companies

14

Necrotizing Enterocolitis Key Products

15

Necrotizing Enterocolitis Unmet Needs

16 

Necrotizing Enterocolitis Market Drivers and Barriers

17

Necrotizing Enterocolitis Future Perspectives and Conclusion

18

Necrotizing Enterocolitis Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Necrotizing Enterocolitis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/